Search for other papers by Anne M Drewes in
Google Scholar
PubMed
Search for other papers by Maria E Møller in
Google Scholar
PubMed
Search for other papers by Rasmus Hertzum-Larsen in
Google Scholar
PubMed
Search for other papers by Gerda Engholm in
Google Scholar
PubMed
Search for other papers by Hans H Storm in
Google Scholar
PubMed
. Apart from ionising radiation, we have limited knowledge on risk factors for brain tumours, and for breast cancer hormone-related factors, for example, null parity, late age pregnancies, overweight, alcohol consumption and genetic mutations ( BRCA1 and
Leeds Institute for Cardiovascular and Metabolic Medicine (LICAMM), University of Leeds, Leeds, UK
Search for other papers by Nikolaos Kyriakakis in
Google Scholar
PubMed
Search for other papers by Marilena Giannoudi in
Google Scholar
PubMed
Search for other papers by Satish S Kumar in
Google Scholar
PubMed
Leeds Institute for Cardiovascular and Metabolic Medicine (LICAMM), University of Leeds, Leeds, UK
Search for other papers by Khyatisha Seejore in
Google Scholar
PubMed
Search for other papers by Georgios K Dimitriadis in
Google Scholar
PubMed
Search for other papers by Harpal Randeva in
Google Scholar
PubMed
Leeds Institute of Medical Research, University of Leeds, UK
Search for other papers by Adam Glaser in
Google Scholar
PubMed
Search for other papers by Michelle Kwok-Williams in
Google Scholar
PubMed
Search for other papers by Georgina Gerrard in
Google Scholar
PubMed
Search for other papers by Carmel Loughrey in
Google Scholar
PubMed
Search for other papers by Ahmed Al-Qaissi in
Google Scholar
PubMed
Search for other papers by Ramzi Ajjan in
Google Scholar
PubMed
Search for other papers by Julie Lynch in
Google Scholar
PubMed
Leeds Institute for Cardiovascular and Metabolic Medicine (LICAMM), University of Leeds, Leeds, UK
Search for other papers by Robert D Murray in
Google Scholar
PubMed
Introduction Malignant brain tumours affect both children and adults, although have markedly different long-term outcomes. Five-year survival rates of 73% have been reported following multi-modality treatment in children diagnosed with
Search for other papers by David S McLaren in
Google Scholar
PubMed
Search for other papers by Aarani Devi in
Google Scholar
PubMed
Search for other papers by Nikolaos Kyriakakis in
Google Scholar
PubMed
Search for other papers by Michelle Kwok-Williams in
Google Scholar
PubMed
Division of Cardiovascular and Diabetes Research, Leeds Institute of Cardiovascular and Metabolic Medicine (LICAMM), University of Leeds, Leeds, UK
Search for other papers by Robert D Murray in
Google Scholar
PubMed
performed in adult survivors of non-pituitary brain tumours showed a comparatively higher prevalence of pituitary dysfunction of 88.8% after a median follow-up of 8 years. For individual axes, growth hormone deficiency (GHD) was the most frequent (86
Search for other papers by Izabelle Lövgren in
Google Scholar
PubMed
Radiotherapy Related Research, The Christie NHS Foundation Trust, Manchester, UK
Search for other papers by Azadeh Abravan in
Google Scholar
PubMed
Search for other papers by Abigail Bryce-Atkinson in
Google Scholar
PubMed
Radiotherapy Related Research, The Christie NHS Foundation Trust, Manchester, UK
Search for other papers by Marcel van Herk in
Google Scholar
PubMed
in Fig. 1 ( 3 ). Standard photon-beam RT treatments deliver 1.8–2.0 Gray (Gy) fractions of radiation dose 5 days a week for 4–6 weeks ( 3 ). The most common types of RT used for paediatric brain tumours are 3D conformal RT (3DCRT) and intensity
AP-HP.Nord-Université de Paris, Hôpital Universitaire Robert Debré, Unité d’Épidémiologie Clinique, Inserm, Paris, France
Search for other papers by Enora Le Roux in
Google Scholar
PubMed
Search for other papers by Florence Menesguen in
Google Scholar
PubMed
Search for other papers by Isabelle Tejedor in
Google Scholar
PubMed
Search for other papers by Marc Popelier in
Google Scholar
PubMed
Search for other papers by Marine Halbron in
Google Scholar
PubMed
Search for other papers by Pauline Faucher in
Google Scholar
PubMed
Search for other papers by Sabine Malivoir in
Google Scholar
PubMed
Search for other papers by Graziella Pinto in
Google Scholar
PubMed
Search for other papers by Juliane Léger in
Google Scholar
PubMed
Search for other papers by Stephane Hatem in
Google Scholar
PubMed
Search for other papers by Michel Polak in
Google Scholar
PubMed
Search for other papers by Christine Poitou in
Google Scholar
PubMed
Search for other papers by Philippe Touraine in
Google Scholar
PubMed
) represent 3492 (36%) of coordination actions. Table 1 Cohort medical characteristics. n (%) Diseases Malignant brain tumour (except craniopharyngioma) 56 (11) Obesity 55 (11) Type 1 diabetes 54 (11
Search for other papers by Laura van Iersel in
Google Scholar
PubMed
Search for other papers by Sarah C Clement in
Google Scholar
PubMed
Princess Máxima Center for Pediatric Oncology, Utrecht, The Netherlands
Search for other papers by Antoinette Y N Schouten-van Meeteren in
Google Scholar
PubMed
Search for other papers by Annemieke M Boot in
Google Scholar
PubMed
Search for other papers by Hedi L Claahsen-van der Grinten in
Google Scholar
PubMed
Search for other papers by Bernd Granzen in
Google Scholar
PubMed
Search for other papers by K Sen Han in
Google Scholar
PubMed
Department of Radiation Oncology, University Medical Center Utrecht, Utrecht, The Netherlands
Search for other papers by Geert O Janssens in
Google Scholar
PubMed
Search for other papers by Erna M Michiels in
Google Scholar
PubMed
Search for other papers by A S Paul van Trotsenburg in
Google Scholar
PubMed
Search for other papers by W Peter Vandertop in
Google Scholar
PubMed
Department of Pediatric Oncology/Hematology, Amsterdam University Medical Center, location VU University Medical Center, Amsterdam, The Netherlands
Search for other papers by Dannis G van Vuurden in
Google Scholar
PubMed
Search for other papers by Hubert N Caron in
Google Scholar
PubMed
Department of Pediatrics, Emma Children’s Hospital, Amsterdam University Medical Center, location Academic Medical Center, University of Amsterdam, Amsterdam, The Netherlands
Search for other papers by Leontien C M Kremer in
Google Scholar
PubMed
Search for other papers by Hanneke M van Santen in
Google Scholar
PubMed
. ( https://doi.org/10.1046/j.1365-2265.2001.01292.x ) 14 Livesey EA Hindmarsh PC Brook CG Whitton AC Bloom HJ Tobias JS Godlee JN Britton J. Endocrine disorders following treatment of childhood brain tumours . British Journal of Cancer 1990 61
Search for other papers by Helga Schultz in
Google Scholar
PubMed
Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark
Search for other papers by Svend Aage Engelholm in
Google Scholar
PubMed
Search for other papers by Eva Harder in
Google Scholar
PubMed
Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark
Search for other papers by Ulrik Pedersen-Bjergaard in
Google Scholar
PubMed
Search for other papers by Peter Lommer Kristensen in
Google Scholar
PubMed
(MSCC) and brain tumours. Diabetes mellitus (DM) is a well-known metabolic side effect from treatment with glucocorticoids. The diabetogenic effect is mainly a result of insulin resistance in muscle and fatty tissue, increased production of glucose from
Search for other papers by Ida Staby in
Google Scholar
PubMed
Search for other papers by Jesper Krogh in
Google Scholar
PubMed
Search for other papers by Marianne Klose in
Google Scholar
PubMed
Search for other papers by Jonas Baekdal in
Google Scholar
PubMed
Department of Clinical Medicine, Faculty of Health and Clinical Sciences, Copenhagen University, Copenhagen, Denmark
Search for other papers by Ulla Feldt-Rasmussen in
Google Scholar
PubMed
Search for other papers by Lars Poulsgaard in
Google Scholar
PubMed
Search for other papers by Jacob Bertram Springborg in
Google Scholar
PubMed
Department of Clinical Medicine, Faculty of Health and Clinical Sciences, Copenhagen University, Copenhagen, Denmark
Search for other papers by Mikkel Andreassen in
Google Scholar
PubMed
Introduction Pituitary adenomas are found in almost all cases of benign tumours with an incidence of around 3–4 per 100,000 and account for approximately 15% of all primary brain tumours ( 1 ). They are categorized into functioning and non
Search for other papers by Nadine M Vaninetti in
Google Scholar
PubMed
Search for other papers by David B Clarke in
Google Scholar
PubMed
Search for other papers by Deborah A Zwicker in
Google Scholar
PubMed
Search for other papers by Churn-Ern Yip in
Google Scholar
PubMed
Search for other papers by Barna Tugwell in
Google Scholar
PubMed
Search for other papers by Steve Doucette in
Google Scholar
PubMed
Search for other papers by Chris Theriault in
Google Scholar
PubMed
Search for other papers by Khaled Aldahmani in
Google Scholar
PubMed
Search for other papers by Syed Ali Imran in
Google Scholar
PubMed
Introduction Sellar masses (SMs) are mostly benign growths of pituitary or non-pituitary origin that are increasingly encountered in clinical practice, accounting for approximately 14–18% of all brain tumours ( 1 , 2 ). SMs typically present
Department of Pediatrics and Adolescent Medicine, Aarhus University Hospital, Aarhus, Denmark
Search for other papers by Mette Marie Baunsgaard in
Google Scholar
PubMed
Department of Pediatrics and Adolescent Medicine, Aarhus University Hospital, Aarhus, Denmark
Search for other papers by Anne Sophie Lind Helligsoe in
Google Scholar
PubMed
Department of Pediatrics and Adolescent Medicine, Aarhus University Hospital, Aarhus, Denmark
Search for other papers by Louise Tram Henriksen in
Google Scholar
PubMed
Department of Pediatrics and Adolescent Medicine, Aarhus University Hospital, Aarhus, Denmark
Search for other papers by Torben Stamm Mikkelsen in
Google Scholar
PubMed
Search for other papers by Michael Callesen in
Google Scholar
PubMed
Search for other papers by Britta Weber in
Google Scholar
PubMed
Department of Pediatrics and Adolescent Medicine, Aarhus University Hospital, Aarhus, Denmark
Search for other papers by Henrik Hasle in
Google Scholar
PubMed
Department of Pediatrics and Adolescent Medicine, Aarhus University Hospital, Aarhus, Denmark
Steno Diabetes Center Aarhus, Aarhus University Hospital, Aarhus, Denmark
Search for other papers by Niels Birkebæk in
Google Scholar
PubMed
outcomes . Journal of Clinical Endocrinology and Metabolism 2019 104 6101 – 6115 . ( https://doi.org/10.1210/jc.2019-00834 ) 18 Gleeson HK Shalet SM . The impact of cancer therapy on the endocrine system in survivors of childhood brain tumours